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ABSTRACT 
Benign prostatic hyperplasia (BPH) is a disease which carries a high public health burden 
as it imposes a decreased quality of life and affects an increasing proportion of men as they age. 
It is known that BPH represents a chronic inflammatory state. Understanding underlying factors 
which drive the etiology of BPH is of utmost importance. One possible causative factor which 
has been considered is sexually transmitted infections.  An association between seroprevalence 
of human herpesvirus 8 (HHV-8), a sexually transmitted infection, and increased risk of prostate 
cancer among a cohort of men in the island of Tobago has been reported. This study aims to 
further examine a potential association between HHV-8 seroprevalence and development of BPH 
through contribution to a chronic inflammatory state.  The HHV-8 seroprevalence was 
determined among 168 men classified as having BPH (elevated serum prostate specific antigen 
levels ≥4.0ng/ml and cancer-free biopsy) and compared to 234 controls (men with normal 
prostates as defined by a PSA <4.0 ng/ml and a normal digital rectal exam) utilizing an enhanced 
immunofluorescence assay. Circulating pro-inflammatory cytokine levels were compared in a 
subset of both groups (120 BPH cases and 87 controls) utilizing the Meso Scale Discovery 
immunoassay.  
A significant difference in percentage of HHV-8 seropositive individuals was observed 
with BPH compared to controls (p=0.000).  A significant difference was also found between all 
abnormal inflammatory prostate conditions (BPH and prostate cancer as compared to controls 
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(p=0.000). Significant differences were observed in mean levels of a majority of serum cytokines 
examined between individuals in BPH case and control groups (p<0.05). Comparison of BPH 
and control groups stratified by infection demonstrated significant differences in mean serum 
levels of a majority of pro-inflammatory cytokines which were examined.     This study was the 
first of its kind to demonstrate a potential association between HHV-8 and BPH, and provided 
preliminary evidence to support increased pro-inflammatory response to BPH disease and HHV-
8 viral infection. Further studies are needed to strengthen this association and provide further 
evidence of an inflammatory cytokine response.  
Statement of Public Health Relevance:  BPH is a disease which affects a significant proportion 
of the men with an estimated prevalence of 90% by the age of 70. This high prevalence places a 
significant burden on the healthcare system, driving up health care costs. Additionally, this 
disease can lead to loss of quality of life.  Understanding underlying risk factors including 
infectious co-factors including those of infective origin will allow healthcare professionals take 
necessary interventions to reduce incidence and ultimately public health burden. 
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1.0  INTRODUCTION 
1.1 HUMAN HERPESVIRUS 8 
Human herpesvirus 8 (HHV-8) also known as Kaposi’s sarcoma-associated herpesvirus is 
the etiologic agent of many cancers including Kaposi’s sarcoma (KS) [1, 2]. HHV-8 was 
discovered in 1994 by Chang and Moore in tissue from AIDS patients with KS lesions [3]. 
HHV-8 is classified as a gamma-2 herpesvirus with a characteristic double-stranded linear DNA 
structure. The genome is 165 kb in size composed of 85 open reading frames (ORFs). These 
ORFs allow the virus to transcribe proteins necessary for replication, latency, and modulation of 
the immune system [4].    
1.1.1 HHV-8 and Cancer 
HHV-8 is associated with several cancers including KS, primary effusion lymphoma 
(PEL), and some forms of multicentric Castleman’s disease.  In 2010, HHV-8 was identified as a 
group 1 carcinogen by the International Agency for Research on Cancer (IARC) due to its 
specific public health threat related to its oncogenic potential [5]. 
1.1.1.1 Kaposi’s Sarcoma 
 
KS manifests itself as raised lesions or nodules which are either red, purple, brown, black 
in color, found on various tissues including skin, mouth, gastrointestinal and respiratory tract [6]. 
The disease was first reported in patients as early as 1872 by Moritz Kaposi, a Hungarian 
Physician who observed the tumor and described it as an “idiopathic multiple pigmented 
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sarcoma of the skin [7].” The disease was characterized as an angioproliferative disorder in older 
men. Later, reports surfaced in 1972 of herpesvirus particles being isolated from KS lesions 
through electron microscopy [8]. In 1994, HHV-8 viral DNA was isolated in a lesion from a 
patient with AIDS [9]. KS lesions have a characteristic shape morphology with infected cells 
having a spindle shape [10, 11]. The incidence of KS varies widely. In the general population, 
the incidence is 1:100,000, while in the HIV infected individuals, its incidence increases 
significantly to 1:20 [8, 11]. Diagnosis of KS can be confirmed only by biopsy of suspected 
lesion and microscopic diagnosis with detection of latent associated nuclear antigen (LANA) [4].   
 
There are multiple variants of KS disease.  These include Classical KS, AIDS-associated 
KS, endemic KS, and iatrogenic KS. In all four forms, reactivation of the virus due to some form 
of immune suppression, enables development of KS.  Classical KS is consistent with the 
angioproliferative disorder first described by Moritz Kaposi.  The disease occurs in older men of 
primarily Mediterranean descent, European Jewish ancestry, as well as eastern African ancestry. 
The disease occurs due to age related immune weakening [12, 13]. AIDS-associated KS is 
present in HIV-infected individuals, primarily males [4, 14].  It is one of the commonest forms of 
KS, and one of the commonest diseases in those with AIDS.  Endemic KS is a form of disease 
primarily prevalent in Africa [15-18]. Immune suppression through HIV allows for the 
propagation and increased prevalence of KS [18].  In this form of KS it is notable that younger 
populations are affected [17-18].  Lastly, Iatrogenic KS, occurs in organ transplant patients. In 
this form of KS, immunosuppression due to the transplantation allows reactivation of HHV-8 
leading to disease [20]. 
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1.1.1.2 Primary Effusion Lymphoma (PEL) 
 
HHV-8 is the etiologic agent of PEL. PEL is a rare B cell non-Hodgkin’s lymphoma with 
a prevalence of 4% overall and a 5-20% prevalence in HIV/AIDS patients [21-23].  PEL mainly 
occurs in body cavities, such as pericardium, pleural space, and peritoneum.  Prognosis for 
patients is poor with median survival time of six months. Diagnosis of PEL includes 
confirmation of HHV-8 infection in addition to examination of suspected tissue [23] 
1.1.1.3 Multicentric Castleman’s Disease 
 
MCD is a disease of lymphoid tissue which progresses in a manner consistent with 
lymphomas. MCD is not classified as a cancer rather a lymphoproliferative disorder, where there 
is hyperplasia of the tissue. However, the disease is highly similar to lymphoma and patients 
often progress on to develop lymphomas. Treatment is the same as with other cancers, which is 
treatment with chemotherapy and/or radiation therapy.  The disease is sometimes found in 
patients co-infected with HIV [24]. 
1.1.2 Tropism and Viral Entry 
HHV-8 infects a number of cell types in vivo.  These include endothelial cells, dendritic 
cells, activated B cells, and activated macrophages. While these cell types can be infected with 
HHV-8 only productive infection has been reported in B cells [25, 26].  Infection requires 
successful entry into cells.  Successful entry is accomplished by a binding receptor, heparan 
sulfate as well as an entry receptor which varies depending on cell type [4, 27]. Entry receptors 
that have been identified include dendritic cell-specific ICAM-3 grabbing nonintegrin (DC-
SIGN), which is expressed on dendritic cells, activated B-cells and macrophages, amino acid 
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transporter protein (xCT), α3β1 integrin receptor, and the ephrin receptor A2 [28]. The binding 
receptor is used to aggregate virus particles to the cell surface and the entry receptor allows viral 
entry through means of endocytosis, or fusion of the viral envelope.  
1.1.3 Epidemiology of HHV-8 
1.1.3.1 Virus Transmission 
 
Transmission of the virus occurs through direct sexual contact as well as non-sexual 
contact. Transmission through salivary exchange is believed to be the means of non-sexual 
contact. The importance of non-sexual contact through saliva cannot be understated [8, 29, 30]. 
In Africa, childhood KS is highly prevalent, and it is believed that the practice of pre-mastication 
of food by the mother leads to high rate of mother to child transmission [31-36]. Laboratory 
evidence suggests that that the HHV-8 virus readily replicates in-vitro in primary oral-derived 
epithelial cells [8, 36]. HHV-8 can enter lifelong latent infection evading immune responses, and 
reactivate into a lytic infection state [4]. This occurs more often in the immunocompromised 
populations.  Healthy individuals are frequently unaffected by primary infections, and in worst 
case may experience diarrhea, fatigue, and rash if viral reactivation occurs [75]. This is in 
contrast where reactivation of the virus in an immunocompromised individual can lead to severe 
disease.  While disease symptomology is likely to be experienced when virus is in a lytic state, 
both states are important in development of HHV- 8 associated cancers [4, 37]. 
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1.1.3.2 Seroprevalence 
 
The seroprevalence of HHV-8 varies depending on geographical region. The 
seroprevalence is less than 10% in northern Europe, Asia, and the United States with an 
estimated 1-3% seroprevalence in blood donors [8]. This increases to about 10-30% in the 
Mediterranean region, and significantly increases to 30-50% in sub-Saharan Africa.  In the 
Caribbean, seroprevalence is estimated to be between 10-20% [8] (Figure 1). 
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Figure reprinted with permission from Nature Reviews Cancer, Mesri et al., Age-standardized 
incidence in males per 100,000 and HHV-8 seroprevalence rates demonstrate a significantly high 
burden in sub-Saharan Africa compared to other geographical areas.
Figure 1. Incidence of Kaposi’s sarcoma and Seroprevalence rates of HHV-8 
7 
1.2 INFLAMMATION 
Inflammation is part of a successful response to bodily injury and/or infection. When 
properly regulated, inflammation serves an effective means to aid in recovery and return to 
homeostasis. However, there are consequences for uncontrolled inflammation. Many substances 
including cytokines, chemokines, growth factors, reactive oxygen and nitrogen species are all 
continually in a state of increased production. All of these factors can have detrimental effect in 
the processes of cell proliferation, cell cycle control, and apoptosis [38].  A number of diseases 
are thought to have increased inflammation as an underlying factor. These include benign 
conditions such as atherosclerosis, rheumatoid arthritis, and peritonitis. Malignancy is also an 
example which has long had a positive association with chronic inflammation [38, 39]. Other 
conditions are in the process of being explored and the role of inflammation and its etiologic 
agent are of interest. One such condition is benign prostatic hyperplasia which is known to have 
an inflammatory etiology [40].  
1.3 DISEASES OF THE PROSTATE 
Potential associations between HHV-8 and diseases of the prostate, both malignant and 
benign, are continually being explored. This section serves to outline two conditions, prostate 
cancer and benign prostatic hyperplasia, and discusses underlying role of inflammation and 
localization of disease. 
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1.3.1 Benign Prostatic Hyperplasia 
Benign prostatic hyperplasia is one of the most common abnormalities of the prostate. 
The disease is characterized by an increase in the cell count leading to overgrowth of two types 
of cells, epithelial and stromal cells [41].  These cells are located in the transition zone and 
periurethral area, which are located in the central part of the organ [42].  This ultimately 
constricts the urethra and leads to symptomology known in the medical field as lower urinary 
tract symptoms (LUTS) [41-44] (Figure 2).  
1.3.1.1 Signs and Symptoms 
 
Some men with BPH will remain asymptomatic and not develop LUTS. For those who 
experience LUTS, these are symptoms either classified as voiding symptoms, also known as 
obstructive symptoms, including urinary hesitation, reduced urinary stream, and straining while 
voiding. The second classification of symptoms involves increased urinary retention and storage, 
also known as irritative symptomology. These symptoms involves, increased urination 
frequency, increased urgency, and pain and/or burning during urination  It is important to note 
that there are other medical conditions which cause LUTS. One such condition is overactive 
bladder and conditions such as this must be ruled out when symptoms consistent with BPH are 
observed [45]. 
  
1.3.1.2 Diagnosis 
 
Diagnosis of BPH involves a number of criteria. The first is an abnormal digital rectal 
examination. Blood tests measuring the prostate specific antigen (PSA) levels are also used. PSA 
is a serine protease produced in the prostate epithelium. A plasma level greater than 4.0 ng/ml is 
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used as the cutoff, indicating abnormalities. Ultrasound is also performed to rule out 
malignancies such as prostate cancer. A number of other tests exist for diagnosis of BPH. These 
include urinalysis to rule out infections and presence of blood.  A test of the overall flow of 
urine, uroflowmetry, detects reduced flow of urine consistent with BPH.  Urethrocystoscopy is a 
technique used to examine the lower urinary tract is also used. Measuring post void residual 
urine volume (PVR) after urination is another important diagnostic tool [46].   
 
1.3.1.3 Risk Factors 
 
Several risk factors have been proposed as potential contributors towards BPH. Age is a 
significant risk factor. BPH affects many men over the age of 50 years. The prevalence of the 
disease increases with age with an alarming 90% prevalence by 70 years of age. [45, 48]  While 
prevalence is high, not all affected individuals experience symptoms. The next risk factor is 
family history. If a family member has the disease, it makes it more likely that the individual will 
develop the condition. Risk factors associated with heart disease also increase the likelihood of 
developing BPH.  These include overweight/obesity, high blood pressure, low High Density 
Lipoprotein (HDL) cholesterol, diabetes, and lack of physical activity [48].  
 
1.3.1.4 Inflammation  
 
One of the most important risk factors in development of BPH is chronic unregulated 
chronic inflammation. The triggering event and/or factor for the BPH inflammation is not 
entirely clear, however infection is one possible factor.  In previous studies, BPH specimens, 
have yielded presence of bacterial and viral strains. In addition, proinflammatory cytokines and 
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chemokines have been found in stromal cells [45].  A number of cytokines and growth factors 
including IL-12, and IL-23 were found to be secreted by stromal cells [45, 49].  The secretion of 
IL-17 as leads to increased downstream production of the cytokines IL-6 and IL-8 [45, 50]. 
Markers of inflammation such as the C-polysaccharide reactive protein (CRP), were also found 
to be upregulated [51]. Other factors such as Prostaglandin-endoperoxide synthase 2 (COX)-2 
have also been found to be upregulated [45, 52].    
 
1.3.1.5 Treatment 
 
A variety of treatment options are available. These vary from watchful waiting to surgical 
therapies. The choice for the patient depends on each individual circumstance [47, 53]. Watchful 
waiting involves monitoring the condition and consulting with a medical professional for 
effective management of the disease. Medical therapies are also available. These include Alpha-
Blockers, 5-alpha-reductase inhibitors (5-ARIs), phosphodiesterase-5 enzyme inhibitors as well 
combination therapies of the aforementioned medications [54].   Minimally invasive procedures, 
including transurethral needle ablation (TUNA), transurethral microwave thermotheraphy 
(TMUT) are other options.  Lastly, a variety of surgical therapies are available including 
prostatectomy, transurethral holmium laser abalation (HoLAP), Transurethral holmium laser 
enucleation (HoLEP), Holmium laser resection (HoLRP), Photoselective vaporization (PVP), 
Transurethral incision (TUIP), Transurethral vaporation (TUVP), and Transurethral resection 
(TURP) [53]. 
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Figure reprinted with permission from New England Journal Medicine, Sarma et al,. The prostate gland 
is shown with benign prostatic hyperplasia causing constriction of the urethra leading to lower urinary 
tract symptoms (LUTS). The localized targets of medical therapies are shown. 
Figure 2. Prostate gland with BPH disease
1.3.1.6 Epidemiology of BPH and LUTS 
As previously mentioned, age is a risk factor.  BPH prevalence is low at 8% of men aged 
31-40 years and prevalence increases to 90% by 70 years of age [48]. Not all BPH causes LUTS, 
which requires treatment. It is estimated that prevalence of LUTS is approximately 50% by age 
of 70 years which is lower than the prevalence of BPH. The odds of developing moderate to 
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severe LUTS, increases with an odds ratio of 1.9 by age of 50 years to an odds ratio of 3.4 by 70 
years of age [48]. 
1.3.2 Prostate Cancer 
Prostate cancer is a significant malignant disease with high incidence. It is the most 
frequently diagnosed cancer in men in the US. It is estimated that in 2014, there will be an 
incidence of 233,000 new cases, with an estimated 29,480 deaths. In men, prostate cancer is the 
second leading cause of all cancer deaths [55].  1 in 7 men will be diagnosed with prostate 
cancer, and of those men, 1 in 36 will die from the disease. The disease involves malignant 
neoplasm which originates in the outer peripheral zone of the prostate gland [57]. 
1.3.2.1 Signs and Symptoms 
 
In the early stages, prostate cancer often presents with no symptoms. It is not until more 
advanced stages of cancer, that may present with symptoms and these may be confused with 
other disorders such as BPH, and these include problems with voiding, such as interrupted 
stream, weak stream, and in the worst scenario, the overall inability to urinate [58].  
1.3.2.2 Diagnosis 
 
Diagnosis of prostate cancer is done through an evaluation of the medical history and a 
physical exam. Many of the same techniques used in diagnosis of BPH is used in prostate cancer. 
In the physical exam, a digital rectal examination is performed. Rectal ultrasound is also used to 
image the prostate. In addition the prostate-specific antigen is also performed.  The prostate 
biopsy is one of the most important techniques to determine cancer if the PSA and/or the DRE 
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suggest that cancer might be present [58].  Histopathology is used to determine the presence of 
cancerous cells in the biopsy. Unfortunately, although biopsies are one of the important 
techniques in diagnosis, they can yield false negatives, and repeat biopsy procedures may be 
required. This is due in part to the fact that the biopsy needle used may not capture the cancerous 
tissue in the prostate [59, 60]. 
1.3.2.3 Risk Factors 
 
There are risk factors which have been positively associated with development of prostate 
cancer. These include family history of prostate cancer, advanced age, and ethnicity.  In terms of 
ethnicity, prostate cancer is more prevalent in African-Americans as compared to Caucasians and 
Asians.  This inequity in increased risk holds true regardless of geographical location [57]. In the 
islands of Trinidad and Tobago, the prevalence of prostate cancer is 3-fold higher in African men 
compared to Asian Indian descent [61-62]. Genetic factors have been identified which increase 
risk of prostate cancer development. These include polymorphisms within the androgen receptor 
gene yielding greater androgenic stimulation. The androgens testosterone and 
dihydrotestosterone have been shown to increase prostate cancer cell growth [63].  
 
1.3.2.4 Inflammation 
 
An association between prostatic inflammation and development of prostate cancer has 
been reported. Epidemiologic studies have demonstrated an increased risk in prostate cancer with 
inflammation with infective etiology. Specifically, infectious agents have been implicated with 
development of prostatitis (prostate inflammation). It is estimated that as of 2008, approximately 
15% of all prostate cancers can be attributed to infectious agents [63, 64].  While a number 
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viruses have been investigated including herpes simplex (HSV), cytomegalovirus (CMV), and 
papillomaviruses, there is no evidence for significant increase in risk. Nevertheless, it is believed 
that infections contribute to a chronic inflammation which increases risk [65]. Infectious agents 
contributing to inflammation are thought to have a synergistic interaction with other sources of 
inflammation including diet, environmental exposures, and changes in hormonal production, 
retrograde urinary reflex and trauma (Figure 3) [54, 57].  Recently, the cytokine IL-6, has been 
given attention for its role in the inflammatory process. IL-6 is involved in cell proliferation, 
apoptosis, differentiation, and angiogenesis.  Specifically, IL-6 has been shown to promote 
prostate cancer cell proliferation as well as inhibit apoptosis IL-6 acts as a growth factor in an 
autocrine and paracrine fashion.  Studies have demonstrated that elevated IL-6, is correlated with 
poorer outcomes. Additionally, the role of the single nucleotide polymorphisms for  IL-6 
cytokine receptor have been explored with preliminary data demonstrating increased risk, via 
overproduction of cytokine or increased sensitivity to cytokine [67-69].  
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Figure reprinted with permission from Nature Reviews Cancer, De Marzo et al., Prostate inflammation 
can originate from a variety of sources including bacterial and viral infections, changes in hormones, 
chemical exposure from the diet, and retrograde urine reflux exposing the urogenital system to uric 
acid.
Figure 3. Sources of prostatic inflammation 
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1.3.2.5 Previous Studies Involving HHV-8 Seroprevalence  
As previously mentioned, HHV-8 can be transmitted sexually. Considering its oncogenic 
potential, our lab has published data from a case-control study consisting of a cohort of 
participants from the Caribbean island nation of Tobago.  The cohort included 138 men from 
Tobago with biopsy confirmed prostate cancer which were designated cases. One hundred forty 
age matched controls from Tobago with no prostate cancer were designated as controls. Controls 
in order to be included had to have normal digital rectal exam, and PSA values less than 
4.0ng/ml. In addition there were 174 men from Trinidad with no diagnostic evidence of prostate 
cancer. The distribution of each control group varied. Tobagonians were 97% African, and 
Trinidadians were 90% Asian Indian descent, and 10% African [70].  
Men with prostate cancer were more likely to be HHV-8 seropositive than their age–
matched cancer free controls (OR 2.24; 95 C.I. 1.29-3.90) [70].  
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1.4 RELATIONSHIP BETWEEN BPH AND PROSTATE CANCER 
The potential relationship between BPH and an increased risk of development of prostate 
cancer is highly controversial and continually debated.  This is in part due to the fact the diseases 
share many traits including similar hormone-dependent growth, and an underlying inflammatory 
component. Currently, general consensus is that BPH is not a precursory condition to prostate 
cancer. Rather, these two conditions are believed to coexist. This is supported by histology and 
localization of the disease. As previously mentioned BPH are characterized by nodules with 
hyperplasia of epithelial and stromal cells in the centrally located transition zone. In contrast to 
prostate cancer which is an adenocarcinoma which primary develops in epithelial cells in the 
peripheral zone (Figure 4) [56].  Studies have found that other risk factors including age and 
family history are strongly predictive of prostate cancer [57]. One recent large scale Danish 
epidemiological study found that there was an increased risk of prostate cancer incidence and 
mortality. The authors of this study concluded that the data does not provide a causal link 
between BPH and Prostate cancer and Scandinavian countries have higher incidence of prostate 
cancer [72]. One theory is that BPH induces a surveillance bias for prostate cancer [71]. While 
this is the case, a more recent study has also demonstrated an increased risk of aggressive 
prostate cancer development in patients with inflammatory BPH.  This study was controlled for 
surveillance bias through analysis of cases and controls in patients with low PSA and patients 
with no indications for prostate biopsy [73]. 
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Figure reprinted with permission from Nature Reviews Cancer, De Marzo et al., Most prostate cancer 
adenocarcinomas occur in the peripheral zone, with prevalence decreasing into the transition zone and no 
prevalence in the central zone. BPH disease occurs with high prevalence in the transition zone 
decreasing into lower prevalence in the central zone.
Figure 4. Prostate localization and disease occurrence 
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1.5 CYTOKINES 
Cytokines are proteins which serve as signaling mediators altering behavior of other 
cells. Cytokines act in an autocrine, paracrine, or and/or endocrine fashion binding to receptors 
on the cell surface leading to signal transduction. The response to the cytokine signal varies and 
includes processes such as cell differentiation, apoptosis regulation, cytolytic activity, and 
chemotaxis.. A few examples which are relevant to this thesis is as follows [76]: 
IFN-γ – Interferon gamma is a pro-inflammatory cytokine produced primarily by Th1 helper 
cells, and to a lesser extent, by natural killer cells. The target of this cytokine include monocytes, 
endothelial cells, and macrophages. Effects include activation, increase in natural killer cell 
activity, increased expression of class I and class II MHC, B and T cell differentiation as well as 
macrophage and granulocyte activation. 
IL-1- Interleukin 1 is a pro-inflammatory cytokine secreted by the activated macrophages, 
monocytes, epithelial cells, endothelial cells, and astrocytes.  Primary targets, include T and B 
cells, endothelial cells, hypothalamus and liver. The effects include T-cell activation. 
IL-2- Interleukin 2 is a pro-inflammatory cytokine produced by Th cells and serves as a growth 
factor for T and B cells. It also activates NK cells and monocytes. 
IL-4- Interleukin 4 is a pro-inflammatory cytokine produced by macrophages and Th2 cells. The 
target cells include naïve Th cells allowing for differentiation into Th2 cells, ultimately important 
for humoral response. 
IL-6- Interleukin 6 is a pro-inflammatory cytokine produced by T cells, Macrophages, and 
Fibroblasts. Its target cells include T and B cells, and liver cells, IL-6 serves as a co-stimulatory 
molecule, and growth factor. IL-6 is implicated in prostate cancer as it has been shown to be 
involved in cell proliferation, apoptosis, differentiation, and angiogenesis.  
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IL-8- Interleukin 8 is a pro-inflammatory cytokine produced by macrophages, epithelial cells, 
platelets. Its target cells include neutrophils.  Its primary effects are activation and chemotaxis.   
IL-10- Interleukin 10 is a pro-inflammatory cytokine produced by Th2 cells. Its primary targets 
include Macrophages and T-cells. The effects include inhibition of antigen presenting cell 
activity and inhibition of cytokine production.  
IL-12- Interleukin 12 is a pro-inflammatory cytokine produced by activated macrophages and 
dendritic cells.  Its primary target includes Naïve T cells allowing differentiation into Th1 helper 
cells ultimately signaling a cellular immunity response. It also aids in IFN-γ production. 
TNFα- is produced by activated macrophages. This cytokine is involved in recruitment of 
neutrophils and macrophages to appropriate sites of infection. As with IL-1, TNF is involved 
with fever responses. 
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1.6 HYPOTHESIS 
As previously described in the Tobago prostate cancer case-control study, data have 
indicated a positive association between HHV-8 and increased risk of development of prostate 
cancer (OR=2.24). Further, it has previously been demonstrated in our lab, that there is increased 
macrophage infiltrate in HHV-8 seropositive men. Given that HHV-8 is an infectious agent and 
sexually transmitted infection, it is hypothesized that HHV-8 establishes a chronic infection in 
the prostate leading to chronic inflammation.  Since BPH is a disease associated with 
inflammation, it is hypothesized that HHV-8 infection contributes to BPH. Further, it is 
hypothesized that serum levels of proinflammatory cytokines will be elevated in men with BPH 
compared to controls.   
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1.7 SPECIFIC AIMS 
The present study is based on a previous published study conducted by a member of our 
lab, Dr. Linda Hoffman utilizing serum samples from a cohort of men the island of Tobago 
collected by Dr. Clareann Bunker Ph.D, in the Department of Epidemiology, University of 
Pittsburgh. This study concluded that HHV-8 seropositivity is significantly elevated in men with 
prostate cancer when compared with control subjects. This suggests that HHV-8 may have a role 
in the development of prostate cancer [70].  
 
One hundred sixty eight serum samples of the Tobago cohort who were diagnosed with 
BPH were obtained from the laboratory of Dr. Clareann Bunker Ph.D. Inclusionary criteria 
included normal baseline biopsy, no prostate cancer diagnosis, and PSA ≥4.0 ng/ml. Patients 
were 40-79 years of age. 
 
Serum samples of patients with a negative diagnosis of prostate cancer (controls) 
previously tested for HHV-8 serology by Hoffman et al. from the Tobago cohort  (n=234) were 
also utilized. 
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1.7.1 Specific Aim 1 
Test the hypothesis that a positive association exists between HHV-8 seroprevalence and 
BPH development by comparing seroprevalence among men aged 40-79 years diagnosed with 
BPH to controls. BPH subjects were defined by PSA ≥4.0 ng/ml, and a normal baseline biopsy. 
The age-matched controls were defined by PSA values of <4.0ng/ml and normal digital rectal 
exam. The HHV-8 serology on the control group was previously determined and reported by 
Hoffman et al. [70]. 
 
Aim 1 is accomplished utilizing an HHV-8 enhanced lytic immunofluorescent assay that 
detects the presence of antibodies to lytic HHV-8 antigens. Screening for seropositivity was 
performed on 168 serum samples from men with BPH. Serology data was compared with 
previously obtained age-matched controls. 
1.7.2 Specific Aim 2 
The specific objectives of AIM 2 were to test the hypothesis that proinflammatory 
cytokine serum levels are elevated among men who are diagnosed with BPH. Further, a second 
objective of this study is to test the hypothesis that HHV-8 causes an increase in the 
proinflammatory cytokines. Comparisons between HHV-8 seropositive men and seronegative 
men in both BPH and control groups will be made. Final comparisons between BPH and control 
diagnosis in seropositive and seronegative groups will be made. 
 
Aim 2 is accomplished through the testing of serum samples of one hundred twenty BPH 
patients; 63 HHV-8 seropositive and 57 HHV-8 seronegative. An age matched control group 
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consisted of 39 HHV-8 seropositive and 48 HHV-8 seronegative samples from men with normal 
PSA and DRE. 
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2.0  MATERIALS AND METHODS 
2.1 CELL CULTURE 
2.1.1 BCBL-1 
The BCBL-1 cell line was developed from a body cavity based lymphoma cell line 
infected with HHV-8 but not EBV. These cells can be induced to produce HHV-8 with the 
phorbol ester, 12-O-tetradecanoylphorbol-13-acetate (TPA). Cells are cultured in RPMI 1640 
with L-glutamine (Corning CellGro # 10-040-CV), 10% heat inactivated Fetal Bovine Serum 
(Gemini #100-506), and 1x Gentamicin (Lonza # 17-518Z).  
2.2 IMMUNOFLUORESCENCE ASSAY 
2.2.1 Slide Preparation 
To determine presence of HHV-8 lytic antigens, immunofluorescence assay was 
performed as previously described [70]. 5mm 12-well slides (Fisher Scientific #12-580-23) were 
coated with 10% poly-l-lysine and allowed to air dry. One liter of BCBL-1 in a T175 flask was 
set up at 2.5x105 cells/ml overnight at 37°C in the incubator. The following day, cells were 
induced with TPA at a final concentration of 20ng/ml.  Cells were allowed to incubate for an 
additional five days.  Following incubation, cells were harvested. Briefly, cells were transferred 
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to 250ml bottles and spun at 3500rpm at room temperature for 25 minutes. Cells were washed 
with 1X PBS three times, reducing volume of PBS wash each time.  Cells were resuspended in 
one-tenth of final volume of PBS wash in 4% buffered paraformaldehyde and incubated for ten 
minutes at room temperature to fix cells. Cells were pelleted and washed twice to remove 
paraformaldehyde. Following incubation, cells were permeabilized in 0.05% Triton-X 100 for 
ten minutes at room temperature. Cell counts were performed using a hemocytometer and cells 
were resuspended in 1X PBS to yield a concentration between 1.5-2.5x107 cells/ml. 10µl Aliquot 
of cell suspension were added to each slide well.  Slides were allowed to air dry and frozen at -
20°C until assay was performed. 
2.2.2 Enhanced Lytic Immunofluorescent Assay 
HHV-8 seroprevalence of serum samples were examined using enhanced lytic 
immunofluorescent assay. Slides were removed from -20°C freezer, and place in a humidified 
chamber for 10 minutes. Following humidification, slides were blocked with 20µl per well of 
10% goat serum (Gibco# 16210) at 37°C for 1 hour. Two dilutions of serum samples (Primary), 
at 1:50, and 1:100 were prepared during incubation period. Following blocking incubation 
period, goat serum was aspirated, and 20µl of each primary sample dilution was added to 
separate wells of individual slide. Primary was allowed to incubate for 1 hour at 37°C. Following 
primary incubation, wells were aspirated and washed in 1x PBS. Secondary monoclonal mouse 
Anti-Human IgG (Fc Specific) Clone CG-7 antibody (Sigma#I-6260) was diluted 1:200 in 10% 
serum and 20ul was added to each well of the slide. Slides were incubated for 37°C for 1 hour. 
Following secondary incubation, wells were aspirated and slides were washed in 1xPBS. Tertiary 
anti-mouse IgG gamma-fluorescein antibody (Roche #100813) was diluted 1:100 in 10% goat 
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serum and added to each well under light sensitive conditions. Slides were incubated for 1 hour 
at 37°C.  Post incubation, tertiary antibody was aspirated and slides were washed in 1x PBS in 
light sensitive conditions. A final overnight incubation step was performed in PBS. Slides were 
analyzed in a blinded manner with a fluorescence light microscope utilizing a 1:50 cutoff value. 
2.3 MESO SCALE DISCOVERY SYSTEM 
The Meso Scale Discovery MSD® immunoassay platform was used to measure the levels 
of pro-inflammatory cytokines in prostate serum samples. The assay is a sandwich immunoassay 
utilizing electrochemiluminescence detection technology. Electrodes within the prepared assay 
plate are attached to capture antibodies specific for the analytes IFN-γ, IL-1β, IL-4, IL-6, IL-8, 
IL-10, IL12p70, (MSD, Proinflammatory Panel 1- K15049D). Serum samples were diluted 
utilizing manufacturer’s supplied diluent at a 2-fold dilution, added in duplicate to the supplied 
96 well plate, and incubated at room temperature shaking for two hours.  Plates were washed 
three times with manufacturer supplied wash buffer and 25µl of manufacturer supplied 
reconstituted detection antibody was added to each well.  Plate was incubated at room 
temperature shaking for two hours.  Following detection, antibody incubation plates were 
washed three times with wash buffer.  150µl of manufacturer supplied read buffer was added to 
each well.  Plates were read on a MSD™ SECTOR imager 2400. Analysis of data was 
performed in MSD™ Discovery Software Suite. Cytokine levels that were below the standard 
curve were given the value of 0, and values above the standard curve were given the highest 
concentration in the standard curve.   
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2.4 STATISTICAL ANALYSIS 
2.4.1 AIM 1 
 
Statistical analysis was performed in the serology study utilizing a two-way contingency table to 
calculate chi-squared value with Fisher’s exact test with significance level p<0.05, as 
appropriate. 
 
2.4.2  AIM 2 
 
Statistical analysis was performed in the pro-inflammatory cytokine study utilizing an 
Independent samples Mann-Whitney U test with significance level at p<0.05 as appropriate.  
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3.0  RESULTS 
3.1 AIM 1 
AIM 1 was performed to test the hypothesis that a positive association exists between 
HHV-8 seroprevalence and BPH, an inflammatory prostate condition.  Among the 168 Tobago 
men with BPH, HHV-8 seroprevalence was found to be 42.9% which was significantly higher 
than the seroprevalence among 140 age-matched cancer-free controls obtained from the Tobago 
HHV-8 prostate cancer study by Hoffman et al.   (22.9%; p=0.000, odds ratio (OR) 2.51, 95% 
confidence interval (CI) 1.48-4.26) (Table 1). A second comparison between HHV-8 serology in 
prostate cancer cases and BPH cases was made to test for differences between these two 
inflammatory mediated conditions.  In the 138 Tobago men with biopsy-confirmed cancer cases, 
HHV-8 seroprevalence was found to be 39.9% which was not significantly different compared to 
BPH cases (42.9% p=0.64, OR=1.12, 95% CI 0.69-1.82). Previous studies have only compared 
prostate cancer and controls, therefore comparison between prostate cancer to any other status, 
including BPH and controls was of interest. Combined BPH and cancer-free control group HHV-
8 seroprevalence was found to be 33.7%. This was not significantly less compared to biopsy-
confirmed prostate cancer group (39.9%, p=0.239, OR= 0.77, 95% CI 0.50-1.18). There was an 
interest in comparing the serology of any abnormal prostate condition (cancer and BPH) to age 
matched controls. HHV-8 seroprevalence was found to be 41.5% in the aggregate group which 
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was significantly greater than age-matched controls (22.9%, p=0.000, OR=2.38, 95% CI 1.48-
3.86). 
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Table 1.  HHV-8 Serology of Men in the Island Nation of Tobago 
HHV-8 Serology Group Comparisons 
p-
value OR(95% CI) 
Tobago BPH (72/168; 42.9%) vs. Age Matched Controls  (32/140; 22.9%) 0.000 2.51(1.48-4.29) 
Tobago BPH (72/168; 42.9%) vs. Prostate Cancer Cases (55/138; 39.9%) 0.643 1.12(0.69-1.82) 
Tobago Prostate Cancer Cases (55/138;39.9%)* 
                                                                                                                          0.003    2.24(1.29-3.90) 
Tobago Age-matched Controls (32/140; 22.9%)* 
  
Tobago Prostate Cancer Cases and Tobago BPH (127/306; 41.5%) vs. 
Tobago Age-matched Controls (32/140; 22.9%) 0.000 2.38(1.48-3.86) 
Tobago BPH Cases and Age-matched Controls (104/209;33.7%) vs. 
Tobago Prostate Cancer (55/138;39.9%) 0.239 0.77(0.50-1.18) 
*Data derived from Tobago HHV-8 prostate cancer study, Hoffman  et al [70]. 
   
Statistical analysis was performed utilizing Chi-squared with Fisher’s exact t-test at significance at p=0.05 
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3.2 AIM 2 
Aim 2 was performed to test the hypothesis that proinflammatory cytokine serum levels 
are higher among men who are diagnosed with BPH as well as men who are HHV-8 
seropositive. Serum samples of one hundred twenty BPH patients; 63 HHV-8 seropositive and 
57 HHV-8 seronegative were used. An age matched control group was established utilizing 
previously obtained and tested samples from the Tobago cohort study selecting 39 HHV-8 
seropositive and 48 HHV-8 seronegative samples. 
 The mean levels of each pro-inflammatory cytokine are listed (Table 2). Notably, IL-8 was 
found to be present in greater mean levels compared to other cytokines in all groups.
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Table 2. Serum Cytokine Levels Stratified by Seropositivity and Case Status 
 
 
Control,  
HHV-8 Seropositive (N=39) 
(pg/ml) 
Controls,  
HHV-8 Seronegative (N=48) 
(pg/ml) 
BPH,  
HHV-8 Seropositive (N=63) 
(pg/ml) 
BPH,  
HHV-8 Seronegative (N=57) 
(pg/ml) 
Cytokine Mean±SD Mean±SD Mean±SD Mean±SD 
IFN-γ 2.22± 2.58 2.28± 2.43 6.99±11.89 5.22± 6.51 
IL-10 0.21± 0.32 0.29± 1.04 0.45± 0.55 0.42± 0.70 
IL-13 0.57± 0.43 0.32± 0.35 0.46± 0.53 0.44± 0.35 
IL-12p70 6.75± 6.52 1.92± 2.21 4.89± 5.35 5.31± 4.74 
IL-1β 1.23± 6.68 0.17± 0.52 1.45± 6.38 0.15± 0.27 
IL-2 0.17± 0.25 0.36± 0.55 1.57± 6.11 0.35± 0.55 
IL-4 0.08± 0.11 0.25± 0.54 0.37± 0.29 0.20± 0.19 
IL-6 21.08± 127.57 1.17± 2.57 8.92± 52.20 1.55± 1.61 
IL-8 251.21± 1392.15 33.04± 84.86 345.84± 820.70 223.53± 564.84 
TNFα 0.40± 0.84 0.77± 2.51 1.92±1.83 1.60± 1.53 
 
An initial comparison was made between controls including all serology and men diagnosed with BPH (Table 3). 
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Table 3. Comparison of Pro-Inflammatory Cytokines between Control and BPH cases 
 
 
Control 
(N=87)  
(pg/ml) 
BPH  
(N=120) 
(pg/ml)   
Cytokine Mean±SD Mean±SD 
p-
value 
IFN-γ 2.22± 2.48 6.15± 9.71 0.000 
IL-10 0.26± 0.80 0.44± 0.62 0.000 
IL-13 0.43± 0.41 0.45± 0.45 0.915 
IL-12p70 4.08± 5.23 5.09± 5.05 0.163 
IL-1β 0.65± 4.49 0.83± 4.65 0.024 
IL-2 0.27± 0.45 0.99± 4.46 0.001 
IL-4 0.17± 0.42 0.28± 0.26 0.000 
IL-6 10.1± 85.40 5.42± 37.87 0.000 
IL-8 
130.84± 
933.92 
287.74± 
710.51 0.000 
TNFα 0.60± 1.95 1.77± 1.70 0.000 
 
Statistical analysis was performed utilizing an independent samples Mann-Whitney U-test with 
significance at p<0.05. 
 
Analyses of the levels of pro-inflammatory cytokines revealed seven out of ten were 
significantly elevated in BPH patients compared to controls (p<0.05). One exception was IL-6 
which was significantly higher among the control group. Two of the cytokines, IL-13 and IL-
12p70 were not significantly different.   
BPH cases and controls groups were individually stratified on the basis of HHV-8 
serology and comparisons were made to determine the effect of HHV-8 infection on pro-
inflammatory cytokine levels. Among the control group, the cytokines IL-13, IL-12p70 and IL 
1β were significantly higher among the HHV-8 seropositive subjects (p<0.05).  There were no 
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significant differences between groups with IFN-γ, IL-6, IL-8 and IL-10 cytokines and TNFα 
(Table 4).  
 
 
 
Table 4. Comparison of Pro-Inflammatory Cytokines in Control Group Stratified by HHV-
8 Serology 
 
 
Controls, HHV-8 
Seropositive (N=39) 
Controls, HHV-8 
Seronegative (N=48)   
Cytokine 
 
(pg/ml) 
Mean +S.D. 
(pg/ml) 
Mean +S.D. 
p-
value 
IFN-γ 2.22± 2.58 2.28± 2.43 0.626 
IL-10 0.21± 0.32 0.29± 1.04 0.590 
IL-13 0.57± 0.43 0.32± 0.35 0.001 
IL-
12p70 6.75± 6.52 1.92± 2.21 0.000 
IL-1β 1.23± 6.68 0.17± 0.52 0.000 
IL-2 0.17± 0.25 0.36± 0.55 0.041 
IL-4 0.08± 0.11 0.25± 0.54 0.000 
IL-6 21.08± 127.57 1.17± 2.57 0.207 
IL-8 251.21± 1392.15 33.04± 84.86 0.778 
TNFα 0.40± 0.84 0.77± 2.51 0.481 
 
Statistical analysis was performed utilizing an independent samples Mann-Whitney U-test with 
significance at p<0.05. 
 
Stratified HHV-8 serology comparison of pro-inflammatory cytokine levels among BPH 
cases showed significantly higher levels of IL-1β, IL-2, and IL-4 among seropositive subjects.  
There were no significant differences in the remaining cytokines between BPH HHV-8 
seropositive and seronegative groups (Table 5).  
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Table 5. Comparison of Pro-Inflammatory Cytokines in BPH group Stratified by HHV-8 
Serology 
 
 
BPH, HHV-8 
Seropositive  
(N=63) 
BPH, HHV-8 
Seronegative  
(N=57)   
Cytokine 
(pg/ml) 
Mean +S.D. 
(pg/ml) 
Mean +S.D. 
p-
value 
IFN-γ 6.99±11.89 5.22± 6.51 0.815 
IL-10 0.45± 0.55 0.42± 0.70 0.556 
IL-13 0.46± 0.53 0.44± 0.35 0.447 
IL-12p70 4.89± 5.35 5.31± 4.74 0.327 
IL-1β 1.45± 6.38 0.15± 0.27 0.001 
IL-2 1.57± 6.11 0.35± 0.55 0.001 
IL-4 0.37± 0.29 0.20± 0.19 0.000 
IL-6 8.92± 52.20 1.55± 1.61 0.688 
IL-8 345.84± 820.70 223.53± 564.84 0.791 
TNFα 1.92±1.83 1.60± 1.53 0.155 
 
Statistical analysis was performed utilizing an independent samples Mann-Whitney U-test with 
significance at p<0.05. 
 
Comparison of circulating pro-inflammatory cytokine levels among BPH cases and 
controls who are HHV-8 seropositive demonstrated significant increases in IFN-γ, IL-10, IL-2, 
IL-4, IL-8 and TNFα in the BPH cases while IL-13 and IL-6 were significantly elevated in the 
controls.  The levels of IL-12p70 and IL-1β were not significantly different between these HHV-
8 seropositive groups (Table 6).    
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Table 6. Comparison of Pro-Inflammatory Cytokines in HHV-8 Seropositive Groups 
 
 
BPH, HHV-8 Seropositive  
(N=63) 
Control,  HHV-8 
Seropositive (N=87)    
Cytokine 
(pg/ml) 
Mean +S.D. 
(pg/ml) 
Mean +S.D. 
p-
value 
IFN-γ 6.99±11.89 2.22± 2.58 0.000 
IL-10 0.45± 0.55 0.21± 0.32 0.000 
IL-13 0.46± 0.53 0.57± 0.43 0.049 
IL-12p70 4.89± 5.35 6.75± 6.52 0.055 
IL-1β 1.45± 6.38 1.23± 6.68 0.521 
IL-2 1.57± 6.11 0.17± 0.25 0.000 
IL-4 0.37± 0.29 0.08± 0.11 0.000 
IL-6 8.92± 52.20 21.08± 127.57 0.000 
IL-8 345.84± 820.70 251.21± 1392.15 0.000 
TNFα 1.92±1.83 0.40± 0.84 0.000 
 
Statistical analysis was performed utilizing an independent samples Mann-Whitney U-test with 
significance at p<0.05. 
 
Comparison of circulating pro-inflammatory cytokine levels among BPH cases and 
controls who are HHV-8 seronegative demonstrated significant increases in IFN-γ, IL-10, IL-
12p70, IL-6, IL-8 and TNFα in the BPH cases while IL-1β and IL-4 were significantly different 
between these HHV-8 seronegative groups (Table 7).   
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Table 7.  Comparison of Pro-Inflammatory Cytokines in HHV-8 Seronegative Groups 
 
 
BPH, HHV-8 
Seronegative  
(N=57) 
Control, HHV-8 
Seronegative  
(N=87)    
Cytokine 
(pg/ml) 
Mean +S.D. 
(pg/ml) 
Mean +S.D. 
p-
value 
IFN-γ 5.22± 6.51 2.28± 2.43 0.000 
IL-10 0.42± 0.70 0.29± 1.04 0.000 
IL-13 0.44± 0.35 0.32± 0.35 0.059 
IL-
12p70 5.31± 4.74 1.92± 2.21 0.000 
IL-1β 0.15± 0.27 0.17± 0.52 0.000 
IL-2 0.35± 0.55 0.36± 0.55 0.069 
IL-4 0.20± 0.19 0.25± 0.54 0.013 
IL-6 1.55± 1.61 1.17± 2.57 0.000 
IL-8 223.53± 564.84 33.04± 84.86 0.000 
TNFα 1.60± 1.53 0.77± 2.51 0.000 
 
Statistical analysis was performed utilizing an independent samples Mann-Whitney U-test with 
significance at p<0.05. 
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4.0  DISCUSSION 
BPH is a prostate disease which is believed to have inflammatory etiology. Underlying 
factors that drive this inflammation include a possible infective origin.  This has been 
demonstrated in studies which have previously found bacterial and viral strains in prostate 
samples [45, 48].  As such, a pro-inflammatory response to a pathogen may lead to chronic 
inflammation. Considering HHV-8 is a sexually transmitted infection and has previously been 
associated with prostate cancer, another disease with an inflammatory etiology, there was interest 
in exploring a potential association between HHV-8 and BPH. This study is one of the first to 
explore this potential relationship.  
4.1 AIM 1 
The objective of AIM 1 was to test the hypothesis that a positive association exists 
between HHV-8 seroprevalence and BPH development. This was accomplished through a case-
control study utilizing serum samples originally collected in the Tobago prostate study [70]. BPH 
cases were defined as men from Tobago 40-79 years old with PSA ≥4.0 ng/ml and normal three-
core baseline biopsy. The control group had PSA values of <4.0ng/ml, and normal digital rectal 
exam. Considering men of African descent including Trinidad and Tobago are found to have 
higher prevalence HHV-8 serology and higher prevalence of prostate diseases, including prostate 
cancer, this population is ideal to study to test for a possible association. Serum samples were 
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examined for HHV-8 antigen utilizing enhanced lytic immunofluorescent assay. This assay is a 
long established method of detecting HHV-8 antigens [74]. 
This study found that HHV-8 seropositivity was significantly higher among men with 
BPH, compared to age-matched controls with almost a two-fold difference in HHV-8 serology 
between these two groups. This alone provides preliminary evidence of a positive association 
between HHV-8 seroprevalence and the development of BPH, however is insufficient. A second 
comparison was made between BPH and prostate cancer cases. As both of these diseases are of 
inflammatory etiology, and there is a positive association of HHV-8 and prostate cancer, there 
was interest in comparing serology in BPH and prostate cancer. Interestingly, there was no 
significant difference with BPH having approximately 3% higher serology. This provides 
additional evidence of a possible association.  A third comparison was made between prostate 
cancer and any other prostate status including BPH and normal prostate condition. If an 
association between BPH and HHV-8 was present, it would be expected that any significant 
difference between prostate cancer and all other prostate status would no longer exist as serology 
levels would increase in the aggregate of BPH and age-matched control group.  The data 
demonstrated that there was an 11 % difference in serology between age-matched control alone 
and the aggregate of Tobago BPH cases and age-matched controls. Additionally, no significant 
difference was observed between the aggregate group and prostate cancer cases.  
Together, these aforementioned results could provide evidence to suggest an association 
between HHV-8 and BPH, however, other factors must be considered. For instance, it is 
estimated 10-20% of biopsies are false negatives, raising the possibility that a patient could have 
prostate cancer instead of BPH, assuming presence of abnormal PSA. Considering our BPH 
patients did not have abnormal digital rectal exam as inclusionary criteria, a reliance is made on 
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abnormal PSA and a normal biopsy.  Therefore, a patient could have prostate cancer incorrectly 
diagnosed as BPH, elevating a potential association. Second, considering there has been 
considerable debate regarding the relationship between BPH and the development of prostate 
cancer, and it has been found that both these conditions can coexist simultaneously, only limited 
conclusions can be made about a possible association between BPH and HHV-8. In order to 
address these concerns, a comparison was performed between all abnormal prostate conditions to 
age-matched controls. Close to a two-fold increase in HHV-8 serology was found in abnormal 
prostate, with a significant difference between two groups.   
These data suggest a possible association with HHV-8 and BPH development. It is 
believed HHV-8 sets up an infection in both a lytic and latent state, which allows for the 
facilitation of chronic inflammation.   
4.2 AIM 2 
The objective of AIM 2 was to test the hypothesis that proinflammatory cytokine serum 
levels were higher among men who were diagnosed with BPH compared to control patients 
without BPH. A second objective was to test the hypothesis that HHV-8 infection causes an 
increase proinflammatory cytokines. Statistical analysis was performed utilizing an independent 
samples Mann-Whitney U-test with significance at p<0.05. 
This was accomplished through the testing of prostate serum samples of one hundred 
twenty BPH patients; 63 HHV-8 seropositive and 57 HHV-8 seronegative. Serum samples for 
tested for IFN-γ, IL-10, IL-13, IL-12p70, IL-1β, IL-2, IL-4, IL-6, IL-8, and TNFα. An age 
matched control group from the Tobago prostate control group selecting 39 HHV-8 positive and 
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48 HHV-8 negative samples. Non-parametric independent sample Mann-Whitney U statistical 
tests were used to test for significant differences between two groups. 
 As BPH is an inflammatory disease, it is expected that there will be an increase in 
inflammatory cytokines present in serum, regardless of serology status. Therefore, a comparison 
was made between the mean levels in the control and the BPH group, and significant differences 
were observed in eight of the ten cytokines including IL-6 and IL-8 (Table 3). This was 
consistent with other reported data indicating presence of increased IL-6 and IL-8 in BPH 
patients [45, 50]. To control for other factors including HHV-8 virus infection, this same 
comparison was made in seronegative individuals (Table 7). Again, a significant elevation in 
cytokines was observed in BPH diagnosed individuals.    
Having observed this phenomenon, control and BPH groups were stratified by HHV-8 
serology status (Table 2, 4, and 5). Examining both the HHV-8 serology stratified control and the 
BPH groups, the level of pro-inflammatory cytokines become significantly elevated in HHV-8 
seropositive individuals, compared to seronegative individuals in both groups.  Supporting this 
observation was the significant elevation in mean cytokine levels in seropositive individuals 
between BPH diagnosed patients and control group (Table 6). This observation is expected 
considering BPH induces significant increase and virus infection also leads to a significant 
increase in cytokine release. Therefore, a synergistic effect is expected. 
In summary, the data support the conclusion that BPH leads to increased cytokine 
response consistent with a chronic inflammatory state. HHV-8 infection was also found to 
contribute to an increased cytokine elevation in BPH cases and control group.  This study was 
the first of its kind to demonstrate a potential association between HHV-8 and BPH, and 
provided preliminary evidence to support increased pro-inflammatory response. Further studies 
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are needed to strengthen this association and provide further evidence of an inflammatory 
cytokine response.  
   
4.3 LIMITATIONS 
While this study was informative, there are limitations which need to be addressed.  This 
study utilized samples from the Island of Tobago, which were obtained between the years 1998-
2000. The possibility exists that the integrity of these samples may have been compromised due 
to mishandling of samples after collection leading a loss of overall representativeness of in vivo 
cytokine levels. Limitations also exist with this study design. This study was a cross-sectional 
study of all serum samples. To get a better understanding of a potential relationship between 
HHV-8 infection and BPH, a longitudinal study should be performed. HHV-8 is a herpes virus, 
and as such has the ability to enter latent and lytic stages. A longitudinal approach would allow 
one to explore associations in each stage. A second issue is the fact that the study did not utilize 
individually age-matched cases and controls. Rather, each entire group was matched by age. 
Because prevalence of BPH varies with age, utilizing matching is importance.  Further, this 
study failed to take into account other possible viral infections, including HIV-1, due to 
restrictions placed by Institutional Review Board. Therefore, limited conclusions on cytokine 
release and modulation can be made.   
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5.0  FUTURE DIRECTIONS 
Future studies should aim to address limitations from this study in order to strengthen 
evidence for a potential association between HHV-8 and benign prostatic hyperplasia. This study 
was this involved an examination of a single time point where sample was collected for each 
study participant. Future studies should be longitudinal observing potential changes in HHV-8 
serology, accompanied pro-inflammatory cytokine release, and prostate health, given that the 
prevalence of this disease increases with age. This would provide more information and help to 
confirm an association.  
While the serology was determined in this study through enhanced immunofluorescence 
assay to establish serology, it would be useful to perform end-point antibody titers utilizing this 
method. From this data, one could examine if a correlation is present between end point titer and 
cytokine profiles. Additionally, In vitro studies in the laboratory measuring pro-inflammatory 
cytokines after HHV-8 infection in prostate cell lines should be performed. 
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6.0  PUBLIC HEALTH SIGNIFICANCE 
Benign Prostatic Hyperplasia is a disease with a prevalence of up to 80% of men 70-79 
years of age, and can reduce quality of life significantly. At the current time, the pathophysiology 
of BPH is not entirely understood. While current evidence suggests inflammation is involved in 
overall etiology, factors which contribute to this inflammation need to be elucidated. This study 
demonstrated a positive association between HHV-8 and development of BPH.  By further 
understanding the way infectious agents contribute to the pathophysiology of this disease and the 
pro-inflammatory response profile in seropositive patients, one can further understand the 
inflammatory process involved in BPH. While it can conceded that many factors besides 
infectious diseases are involved and may have an interaction in increasing risk of development of 
BPH, this study provides a foundation to gain an understanding about the role of an infectious 
co-factor. Upon validation of this research, one can use this data to emphasize measures to 
prevent spread of sexually transmitted infections including HHV-8.  Further understanding of 
other factors and their contributing role in inflammatory pathway including diet, environmental, 
hormonal, and genetic factors could allow the eventual reduction of disease burden. 
46 
BIBLIOGRAPHY 
1.  Moore P.S. and Chang Y., “Kaposi's Sarcoma-Associated Herpesvirus,”Fields  
Virology, 4th ed. edited by D. M. Knipe and P. M. Howley (Lippincott  
Williams and Wilkins, Philadelphia, 2001), pp.2803-2833.   
 
2.  Moore P.S. and Chang Y., “Molecular virology of Kaposi's sarcoma-associated  
herpesvirus,” Philos. Trans. R. Soc. Lond B Biol. Sci. 2001. 356(1408):499. 
 
3.  Chang Y., et al., “Identification of herpesvirus-like DNA sequences in AIDS-  
associated Kaposi's sarcoma,” Science. 1994. 266 (1865).  
 
4.  Ganem D., “Kaposi's Sarcoma-Associated Herpesvirus.” 5th ed. Fields Virology, ed. 
Edited by S.E. Straus, (Lippincott Williams and Wilkins, Philadelphia, 2007), 
 
5.  IARC (2012). Kaposi’s sarcoma herpesvirus IARC Monogr Eval Carcinog Risks Hum, 
100B: 169–214.  
 
6.  Dezube B.J., “Clinical presentation and natural history of AIDS-related Kaposi 
Sarcoma.” Hematol Oncol Clin North Am. 1996 10(5):1023-9. 
 
7.  Kaposi M., “Idiopathisches Multiples Pigment Sarcoma De Haut.” Arch Dermatol 
Syphil,1872. 4. 
 
8.  Mesri, E.A., Cesarman E., and Boshroff C.., “Kaposi’s sarcoma and its associated 
herpesvirus.” Nat Rev Cancer 2010 10(10):707-719. 
 
9.  Giraldo G., Beth E and Haguenau F., “Herpes-type virus particles in tissue culture of 
Kaposi’s sarcoma from different geographic regions.” J Natl Cancer Inst. 1972. 49:1509-
1526 
 
10.  Tappero J. W., et al., “Kaposi's sarcoma. Epidemiology, pathogenesis, histology,  
clinical spectrum, staging criteria and therapy,” J Am Acad Dermatology. 1993. 
28(3):371-395.   
 
11.  Szajerka T.and Jablecki J., “Kaposi's sarcoma revisited,” AIDS Rev. 2007. 9(4), 230.   
 
12.  Cattani, P. et al., “Age-specific seroprevalence of Human Herpesvirus 8 in Mediterranean 
regions,” Clin Microbiol Infect. 2003. 9(4):274-9. 
47 
 
13.  Anderson, L.A., et al., “Risk factors for classical Kaposi sarcoma in a population-based 
case-control study in Sicily.” Cancer Epidemiol Biomarkers Prev, 2008. 17(12):343543. 
 
14.  Chang, Y., et al., “Identification of herpesvirus-like DNA sequences in AIDS-associated 
Kaposi's sarcoma.” Science, 1994. 266(5192):1865-9. 
 
15.  Gallo, R.C. “The enigmas of Kaposi’s Sarcoma.” Science. 1998. 288:1837-1839. 
 
16.  Oettle A.G. “Geographical and racial differences in the frequency of Kaposi’s sarcoma as 
evidence of environmental and genetic causes.” Acta Unio Int. Contra Cancrum. 1962. 
18:330-363. 
 
17.  Slavin G., et al., “Kaposi’s sarcoma in East African Children: a report of 51 cases. J 
Pathol. 1970. 100:187-199. 
 
18.  Bhagwat, G.P., et al., “Disseminated lymphadenoapthic Kaposi’s sarcoma in Zambian 
children.” Med J. Zambia 1980. 14:61-63. 
 
19.  Wabinga H.R., et al., “Cancer in Kampala, Uganda in 1989-1991: changes in incidence in 
the era of AIDS.” Int J Cancer 1993. 54:26-36. 
 
20.  Siegel J.H. et al. “Disseminated visceral Kaposi’s sarcoma. Appearance after human 
renal homograft operation.” JAMA. 1969;207(8):1493-1496. 
 
21.  Cesarman E., et al., “Kaposi's sarcoma-associated herpesvirus-like DNA  
sequences in AIDS-related body-cavity-based lymphomas.” 1995. 332:1186.  
 
22.  Carbone A. and Gloghini A., “KSHV/HHV8-associated lymphomas,” Br. J.  
Haematol. 2008. 140(1):13. 
   
23.  Chen Y., et al, “Primary Effusion Lymphoma.” The Oncologist. 2007.12(5):569-576  
 
24.  Hengge, U.R., et al., “Update on Kaposi's sarcoma and other HHV8 associated diseases. 
Part 2: pathogenesis, Castleman's disease, and pleural effusion lymphoma.” Lancet Infect 
Dis. 2002. 2(6):344-352. 
 
25.  Rappocciolo, G., et al., “DC-SIGN is a receptor for human herpesvirus 8 on dendritic 
cells and macrophages.” J Immunol. 2006. 176(3):1741-1749. 
 
26.  Rappocciolo, G., et al., Human herpesvirus 8 infects and replicates in primary cultures of 
activated B lymphocytes through DC-SIGN. J Virol.2008. 82(10):4793-4806. 
 
27.  Sarid, R., Olsen S.J., and Moore P.S., “Kaposi's sarcoma-associated herpesvirus: 
epidemiology, virology, and molecular biology.”Adv Virus Res. 1999. 52:139-232. 
 
48 
28.  Knowlton, E.R., et al., “Professional antigen presenting cells in human herpesvirus 8 
infection.” Frontiers. 2013. 3:427. 
 
29.  Pauk, J. et al., “Mucosal shedding of human herpesvirus 8 in men.” N Engl J Med. 2000. 
343(19):1369-1377 
 
 
30.  Martro, E. et al., “Risk Factorsfor human Herpesvirus 8 infection and AIDS-associated 
Kaposi’s sarcoma among men who have sex with men in a European multicenter study.” 
Int J. Cancer, 2007. 120:1129-1135 
 
31.  Mbulaiteye, S., et al., “Molecular evidence for mother-to-child transmission of Kaposi 
sarcoma-associated herpesvirus in Uganda and K1 gene evolution within the host.” J 
Infect Dis, 2006. 193(9):1250-7. 
 
32.  Malope, B.I., et al., “Transmission of Kaposi sarcoma-associated herpesvirus between 
mothers and children in a South African population.” J Acquir Immune Defic Syndr, 
2007. 44(3):351-5. 
 
33. Wojcicki, J.M., “Traditional behavioural practices, the exchange of saliva and HHV-8 
transmission in sub-Saharan African populations.” Br J Cancer. 2003. 89(10):2016-7. 
 
34. Guech-Ongey, M., et al., “HLA polymorphisms and detection of kaposi sarcoma 
associated herpesvirus DNA in saliva and peripheral blood among children and their 
mothers in the uganda sickle cell anemia KSHV Study.” Infect Agent Cancer, 2010. 5: 
21. 
 
35.  Romano, R., “Human Herpesvirus 8 (HHV-8): Salivary Shedding in Mothers and 
Children from Uganda: Risk Factors and Clues about Transmission.” Prevention and 
Research 2011. 1: 44-52. 
 
36.  Mbulaiteye, S.M. and J.J. Goedert, “Transmission of Kaposi sarcoma-associated 
herpesvirus in sub-Saharan Africa.” AIDS. 2008. 22(4):535-537. 
 
37.   Ou, J. H. J. & Yen, T. S. B. Human oncogenic viruses. (World Scientific, 2010) 
 
38.  Hussain, S. P. & Harris, C. C. “Inflammation and cancer: an ancient link with novel  
potentials. International journal of cancer.” Journal international du cancer 2007. 
121:2373-2380. 
 
 
39. Coussens, L. M. & Werb, Z. Inflammation and cancer. Nature. 420:860-867,  
2002.  
 
40.  Fibbi B. et al. “Chronic inflammation in the pathogenesis of benign prostatic 
hyperplasia.” Int J Androl. 2010. 33(3):475-88. 
49 
 
41.  Mishra V.C., Allen D.J., Nicolaou C., et al. “Does intraprostatic inflammation have a role 
in the pathogenesis and progression of benign prostatic hyperplasia?” BJU Int. 
2007;100:327–331            
 
42.  Cotran R.S., Kumar V., Robbins S.L. Male genital system. In: Robbins Pathologic Basis 
of Disease. 5th ed. Philadelphia, Pa.: Saunders;1994. 
 
43. Nickel J.C., “Inflammation and benign prostatic hyperplasia.” Urol Clin North Am. 
2008;35:109–115 
 
44  Nickel JC. “Prostatic inflammation in benign prostatic hyperplasia — the third 
component?” Can J Urol.1994;(1):1–4. 
 
45  Chughtai B., et al., “Role of Inflammation in Benign Prostatic Hyperplasia” Rev Urol. 
2011; 13(3): 147–150. 
 
 
46. Madsen F. A., Bruskewitz. R. C. “Cystoscopy in the evaluation of benign prostatic 
hyperplasia.” World Journal of Urology. 1995. 13(1):14-16. 
 
 
47.  Burnett, A.L. et al. “Benign Prostatic Hyperplasia in Primary Care: “What You Need to 
Know.” The Journal of Urology, 175(3): S19 -24. 
 
48.  McVary K.T.. “BPH: epidemiology and comorbidities.” Am J Manag Care. 2006;129 
suppl 50:S122-128. 
 
49.  McDowell M.E., Occhipinti S., Gardiner R.A., et al. “A review of prostate-specific 
antigen screening prevalence and risk perceptions for first-degree relatives of men with 
prostate cancer.” Eur J Cancer Care. 2009. 18:545–555. 
 
50.  Steiner G.E., Newman M.E., Paikl D., et al. “Expression and function of pro-
inflammatory interleukin IL-17 and IL-17 receptor in normal, benign hyperplastic, and 
malignant prostate.” Prostate. 2003. 56:171–182. 
 
51. Lehrer S., Diamond, E.J.,  Mamkine, B., Droller, M.J.,Stone, N., Stock, R.G., “C-reactive 
protein is significantly associated with prostate-specific antigen and metastatic disease in 
prostate cancer” BJU International. 2005. 7:(14);961-962. 
 
52. Wang et al. “Chronic Inflammation in benign prostate hyperplasia is associated with 
focal upregulation of cyclooxygenase-2, Bcl-2, and cell proliferation in the glandular 
epithelium.” Prostate. 2004. 61;60-72. 
 
53. McVary K.T., et al., “Guideline on the management of benign prostatic hyperplasia 
(BPH).” American Urological Association.  2010. 1-62 
50 
 
54.  Sarma et al. “Benign Prostatic Hyperplasia and Lower Urinary Tract Symptoms” N Engl 
J Med  2012. 367: 248-57. 
 
55.  National Cancer Institute “ SEER Stat Fact Sheets: Prostate Cancer” 2014. 
 
56.  De Marzo A.M. et al., “Inflammation in prostate carcinogenesis” Nat Rev Cancer. 2007. 
7:256-269. 
 
57.  Routh J. C. and Leibovich B. C., "Adenocarcinoma of the prostate: epidemiological  
trends, screening, diagnosis, and surgical management of localized  
disease," Mayo Clin. Proc. 2005. 80(7):899. 
 
58.  American Cancer Society, cancer facts and figures (American Cancer Society  
Press, Atlanta, 2006) 
 
59.  Stroumbakis N., et al., “Clinical significance of repeat sextant biopsies in prostate cancer 
patients.” Urology. 1997;49(3A Suppl):113. 
 
60.  Ellis W.J., “Brawer M.K., “Repeat prostate needle biopsy: who needs 
it?”Urol.1995;153(5):1496 
 
61. Bunker C.H. et al., “Prostate cancer risk is three-fold higher among men, aged  
50-64, of African descent compared with men of Asian-Indian descent in  
Trinidad and Tobago.” 2002. 12, S3-S3-33.  
 
62.  Bunker C.H. et al., “High prevalence of screening-detected prostate cancer  
among Afro-Caribbeans: The Tobago prostate cancer survey,” 2002. 11:726.   
 
63.  Knabbe C. et al., "Growth factors in human prostate cancer cells: implications for  
an improved treatment of prostate cancer," J. Steroid Biochem. Mol. Biol. 1991. 
40(1-3), 185  
 
64.  Nelson W. G., et al., "The role of inflammation in the pathogenesis of prostate  
cancer,” J. Urol. 2004. 172(5 Pt 2), S6. 
 
 65.  Stock D., Groome P. A., and Siemens D. R, “Inflammation and prostate cancer: a  
future target for prevention and therapy?,” Urol. Clin. North Am.  2008. 35(1), 117.   
 
66.  Strickler H. D.and Goedert J. J., “Sexual behavior and evidence for an infectious  
cause of prostate cancer,” Epidemiol. Rev. 2002. 23, 144-151. 
 
67.  Giovannucci et al. “The CAG repeat within the androgen receptor gene and its `
 relationship to prostate cancer” PNAS. 1997. 94(7):3320-3233. 
 
68.  Chung, T.D. et al., "Characterization of the role of IL-6 in the progression of  
51 
prostate cancer," Prostate. 1999 38(3):199.  
 
69. Nguyen D.P., Li J., Tewari A.K.. Inflammation and prostate cancer: the role of 
Interleukin 6 (IL-6) BJU Int. 2014 Jun;113(6):986-92.  
 
70.  Hoffman L.J., et al., "Elevated seroprevalence of human herpesvirus 8 among  
men with prostate cancer," J. Infect. Dis. 189(1), 15 (2004).   
 
71.  Chang R.T.., Kirby R., Challacombe B.J., Is there a link between BPH and prostate 
cancer? Practitioner. 2012 Apr;256(1750):13-6, 2. 
 
72.  Orsted D.D., Bojesen S.E., Nielsen S.F., Nordestgaard B.G. “Association of clinical 
benign prostate hyperplasia with prostate cancer incidence and mortality revisited: a 
nationwide cohort study of 3,009,258 men. Eur Urol. 2011;60(4):691-8 
 
73.  Gurel B. et al., “Chronic inflammation in benign prostate tissue is associated with high-
grade prostate cancer in the placebo arm of the prostate cancer prevention trial.” Cancer 
Epidemiol Biomarkers Prev. 2014;23(5):847-56. 
 
74. Lennette E.T., Blackbourn D.J., Levy J.A.. “Antibodies to human herpesvirus type 8 in 
the general population and in Kaposi's sarcoma patients.” Lancet. 1996;348:858-61. 
 
75. Wang Q.J., et al., “Primary human herpesvirus 8 infection generates a broadly specific 
CD8(+) T-cell response to viral lytic cycle proteins.” Blood. 2002;99(10):3499.  
 
76.  Murphy, K. “Janeway’s Immuno Biology”9th ed. New York, NY.: Garland 
Science;2012. 
